A*STAR

Preclinical Programme Leader, Cardiovascular & Metabolic Diseases

A*STAR
ResearchSingaporeOnsitePosted 3 weeks ago

About the role

AI summarised

Join NATi, Singapore's national platform for nucleic acid therapeutics, as a Preclinical Programme Leader. This role drives the discovery toward clinical development of siRNA/ASO programmes targeting MASH, obesity, and cardiometabolic diseases. You will own the end-to-end scientific and project strategy, transitioning from hands-on execution to building and mentoring a team while managing pipeline programmes within budget and timeline.

ResearchOnsite

Key Responsibilities

  • Own end-to-end scientific and project strategy for siRNA/ASO discovery programmes from target validation to selection of a Preclinical Candidate in MASH, obesity, and/or musculoskeletal diseases.
  • Establish and execute integrated in vitro and in vivo workflows to generate robust, high-quality data supporting decision-making.
  • Drive clear go/no-go recommendations based on integrated assessment of biology, PK/PD, and disease-relevant efficacy endpoints.
  • Ensure scientific rigour, reproducibility, documentation, and transparency across internal and CRO-executed activities.
  • Design, execute, and optimize in vitro screening cascades for siRNA/ASO programmes across key metabolic tissues (liver, muscle, adipose).
  • Develop and deploy mechanistic cell-based assays linking target knockdown with metabolic pathway modulation.
  • Design, oversee, and interpret in vivo PK/PD, biodistribution, and knockdown efficacy studies.
  • Partner with senior management to align programme execution with portfolio strategy, resourcing, and milestone delivery.

Requirements

  • PhD in Molecular Biology, Pharmacology, Biochemistry, or related discipline.
  • Minimum of 4+ years industry experience (Scientist level) leading siRNA/ASO discovery programmes.
  • Minimum of 8+ years industry experience (Senior Scientist level) leading siRNA/ASO discovery programmes.
  • Minimum of 12+ years industry experience (Principal Scientist level) leading siRNA/ASO discovery programmes.
  • Strong hands-on expertise in cell-based screening and mechanistic assays.
  • Proven experience with in vivo PK/PD and knockdown biology studies.
  • Demonstrated success in early drug discovery, from target validation through hit identification and lead generation.
  • Experience establishing new capabilities or scaling programmes through CRO partnerships.